Literature DB >> 15023356

Cdk5, a therapeutic target for Alzheimer's disease?

Li-Huei Tsai1, Ming-Sum Lee, Jonathan Cruz.   

Abstract

Alzheimer's disease (AD) represents the leading cause for senile dementia affecting more than 4 million people worldwide. AD patients display a triad of pathological features including brain atrophy caused by neuronal loss, beta-amyloid plaque and neurofibrillary tangles. We previously show that Cyclin-dependent kinase 5 (Cdk5) is deregulated in AD brains and may contribute to the pathogenesis of AD. In AD brains, a calpain cleavage product of its physiological regulator p35, p25 is elevated. p25 causes prolonged activation of Cdk5 and alteration of its substrate specificity. The implications of p25/Cdk5 in neurotoxicity, beta-amyloid plaque and neurofibrillary tangle pathology will be discussed.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15023356     DOI： 10.1016/j.bbapap.2003.11.019

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


  27 in total

Review 1.  Role of cell cycle re-entry in neurons: a common apoptotic mechanism of neuronal cell death.

Authors:  Jaume Folch; Felix Junyent; Ester Verdaguer; Carme Auladell; Javier G Pizarro; Carlos Beas-Zarate; Mercè Pallàs; Antoni Camins
Journal:  Neurotox Res       Date:  2011-10-01       Impact factor: 3.911

2.  Membrane cholesterol modulates {beta}-amyloid-dependent tau cleavage by inducing changes in the membrane content and localization of N-methyl-D-aspartic acid receptors.

Authors:  Alexandra M Nicholson; D Nicole Riherd Methner; Adriana Ferreira
Journal:  J Biol Chem       Date:  2010-11-03       Impact factor: 5.157

3.  A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation.

Authors:  Ya-Li Zheng; Niranjana D Amin; Ya-Fang Hu; Parvathi Rudrabhatla; Varsha Shukla; Jyotshnabala Kanungo; Sashi Kesavapany; Philip Grant; Wayne Albers; Harish C Pant
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

4.  Inhibition of the cdk5/MEF2 pathway is involved in the antiapoptotic properties of calpain inhibitors in cerebellar neurons.

Authors:  Ester Verdaguer; Daniel Alvira; Andrés Jiménez; Victor Rimbau; Antoni Camins; Mercè Pallàs
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

5.  Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies.

Authors:  Joao P Lopes; Catarina R Oliveira; Paula Agostinho
Journal:  Cell Mol Neurobiol       Date:  2007-10-27       Impact factor: 5.046

6.  The role of Cdk5-mediated apurinic/apyrimidinic endonuclease 1 phosphorylation in neuronal death.

Authors:  En Huang; Dianbo Qu; Yi Zhang; Katerina Venderova; M Emdadul Haque; Maxime W C Rousseaux; Ruth S Slack; John M Woulfe; David S Park
Journal:  Nat Cell Biol       Date:  2010-05-16       Impact factor: 28.824

7.  CHOLESTEROL AND NEURONAL SUSCEPTIBILITY TO BETA-AMYLOID TOXICITY.

Authors:  Alexandra M Nicholson; Adriana Ferreira
Journal:  Cogn Sci (Hauppauge)       Date:  2010-07-01

8.  S-nitrosylation of Cdk5: potential implications in amyloid-β-related neurotoxicity in Alzheimer disease.

Authors:  Jing Qu; Tomohiro Nakamura; Emily A Holland; Scott R McKercher; Stuart A Lipton
Journal:  Prion       Date:  2012-08-09       Impact factor: 3.931

9.  A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.

Authors:  Varsha Shukla; Ya-Li Zheng; Santosh K Mishra; Niranjana D Amin; Joseph Steiner; Philip Grant; Sashi Kesavapany; Harish C Pant
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

Review 10.  Mechanism-based treatments for Alzheimer's disease.

Authors:  Peter Davies; Jeremy Koppel
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.